Customize
Quick Links
Specialties

Accreditation/Credit Designation

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669 for 1.5 Contact Hours.

Acknowledgement of Commercial Support

This activity is supported by educational grants from Takeda Oncology, Genomic Health, and Novartis

Community Practice Connections™: 1st Annual European Symposium on Lung Cancers™

Release Date: August 31, 2017
Media: Internet - based

 

Activity Overview

Community Practice Connections™: 1st Annual European Symposium on Lung Cancers™ features a summary of clinical evidence guiding best practices in the treatment of patients with non–small cell lung cancer (NSCLC), including recent developments with targeted agents and immunotherapy. Interactive clinical vignettes are followed by short video interviews with internationally renowned experts in the management of patients with NSCLC. The video interviews address decision points in the clinical vignettes and questions commonly faced in the community oncology practice setting by medical professionals engaged in the care of patients with NSCLC.

Acknowledgement of Commercial Support

This activity is supported by educational grants from Takeda Oncology, Genomic Health, and Novartis

CME/CE Activity Table of Contents

  • Module 1: Immunotherapy
  • Module 2: ALK
  • Module 3: EGFR
  • Module 4: BRAF

Instructions for This Activity and Receiving Credit

  • You will need to login to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review videos/content until you finish the presentation.
  • At the end of the activity, “educational content/video files” will be available for your reference.
  • In order to receive a CME/CE certificate, participants must complete the activity.
  • Complete the posttest and pass with a score of 70% or higher, complete the evaluation and then click on request for credit. Participants may immediately download a CME/CE certificate upon completion of these steps.

Target Audience

This educational activity is directed toward medical oncologists, radiation oncologists, thoracic surgeons, pulmonologists, and other healthcare professionals involved in the treatment and management of patients with lung cancer. .

Learning Objectives

At the conclusion of this activity, you should be better prepared to:

  • Assess methods by which prognostic and predictive tumor characteristics can be identified in advanced forms of lung cancer
  • Utilize tumor and patient characteristics to optimize personalized treatment sequencing for patients with advanced NSCLC
  • Discuss current and emerging roles for single-agent and combination immunotherapeutic strategies in the management of advanced lung cancers
  • Apply personalized approaches to manage EGFR-mutated advanced NSCLC by assessment of mutation subtypes in multiple lines of care
  • Assess evolving data sets concerning the use of ALK inhibition in frontline and subsequent lines of care in advanced NSCLC
  • Discuss emerging targeted approaches for oncogenic drivers in NSCLC beyond EGFR and ALK
  • Identify approaches to address treatment-related toxicities in patients with lung cancer
  • Integrate personalized approaches to manage challenging cases in advanced lung cancer settings

Faculty, Staff, and Planners' Disclosures

Faculty

Prof. Dr. med. Martin Reck
Head of the Thoracic Oncology and Clinical Trial Departments
Lung Clinic Grosshansdorf
Grosshansdorf, Germany
 

Disclosure: Consultant/Advisory Boards: oche, Lilly, AstraZeneca, Merck Sharp & Dohme, Bristol-Myers Squibb, Boehringer Ingelheim, Pfizer, Novartis, Celgene; Speakers Bureau: Roche, Lilly, AstraZeneca, Merck Sharp & Dohme, Bristol-Myers Squibb, Boehringer Ingelheim, Pfizer, Novartis, Celgene.

Enriqueta Felip MD, PhD
Director Thoracic and Head and Neck Program
Department of Medical Oncology
Vall d'Hebron University Hospital
Barcelona, Spain
 

Disclosure: Consultant/Advisory Boards: Roche, Lilly, AstraZeneca, Merck Sharp & Dohme, Bristol-Myers Squibb, Boehringer Ingelheim, Pfizer, Novartis, Celgene; Speakers Bureau: Roche, Lilly, AstraZeneca, Merck Sharp & Dohme, Bristol-Myers Squibb, Boehringer Ingelheim, Pfizer, Novartis, Celgene.

Tony Mok, MD
Chairman, Dept. of Clinical Oncology
The Chinese University of Hong Kong
Hong Kong, China
 
 

Disclosure: Grant Research Support: AstraZeneca, Boehringer Ingelheim, Pfizer, Novartis, SFJ, Roche, Merck Sharp & Dohme, Clovis Oncology, Bristol-Myers Squibb, Eisai, Taiho; Consultant/Advisory Boards: AstraZeneca, Roche/Genentech, Pfizer, Lilly, Boehringer Ingelheim, Clovis Oncology, Merck Serono, Merck Sharp & Dohme, Novartis, SFJ, ACEA Boehringer Ingelheim Sciences, Vertex, Bristol-Myers Squibb, GeneDecode, OncoGenex, Celgene, Ignyta, Cirina; Shareholder: Sanomics Limited.

Solange Peters, MD-PhD, PD-MER
Head Medical Oncology
Chair Thoracic Malignancies
Oncology Department
Lausanne University Hospital
Lausanne, Switzerland

Disclosure: No relevant financial relationships with commercial interests..

The staff of PER® have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME/CE activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME/CE activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME/CE activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.

CME/CE Provider Contact Information

Physicians’ Education Resource®, LLC
2 Clarke Drive
Suite 110
Cranbury, NJ 08512
info@gotoper.com

Hardware And Software Requirements 

Supported Browsers
Internet Explorer v.7 or greater (for Windows) | Mozilla Firefox v.2 or greater (for Windows, Mac, Linux)

Minimum System Requirements (Windows)

  • A Pentium-based PC or compatible computer
  • At least 64MB of RAM
  • Windows 95/98/NT/ME/2000/XP/Vista system software
  • Screen resolution of 1024 x 786 or larger recommended
  • PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise

Minimum System Requirements (Mac OS)

  • A PowerPC processor-based Macintosh computer
  • At least 64MB of RAM
  • Mac OS 7.5 or later
  • Screen resolution of 1024 x 786 or larger recommended
  • PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise






Become a Member

Forgot Password?
Filter By